South Korea has developed a second stem cell treatment
A second stem-cell treatment, hearticellgram-ami, is expected to be approved this month after South Korea won approval for the world's first stem-cell treatment for coronary heart disease, yonhap news agency said.
South Korea's food and drug agency said it may approve production licenses for medi-post's cartilage regeneration drug Cartistem and Anterogen's anal fistula treatment Cuepistem and some others, by the middle of this month.
Medi-post's Cartistem is a drug specifically tailored to treat degenerative arthritis and damaged knee cartilage, based on stem cells extracted from umbilical cord blood, according to the report. It is worth noting that Cartistem does not use the patient's own stem cells, but other people's stem cells, so if the production license is obtained, it will be the world's first treatment drug produced using other people's stem cells. The advantage is that it can be mass produced.
Anterogen's Cuepistem is a drug created from stem cells taken from a patient's own adipose tissue to treat a complex clonogenic anal fistula.
- April 15, 2019Atlanta, Georgia World Congress Center, 30th of March to 3rd of AprilALIT Life Science presented its latest innovations on the exhibition of the 111th Annual Meeting of the American Association of Can...view
- June 18, 2019At present, one out of every four cancer deaths in China is gastric cancer. Beijing, Jan. 29 (xinhua) -- this year's world cancer day will aim to reduce the risk of cancer through scientific measures ...view
- March 25, 2019The 195th Oriental Science and Technology Forum was held in Shanghai recently. Experts at home and abroad have discussed the effects of microenvironment and systemic factors on the growth of bone tumo...view